Lu-177 Vipivotide Tetraxetan Yields Similar OS Versus Cabazitaxel in mCRPC Progressing After Docetaxel
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA. JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010
ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP
Choosing Chemotherapy for Castration-Resistant Prostate Cancer
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer - Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier ...
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Cancers | Free Full-Text | Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - ScienceDirect
Journal of Clinical Oncology on X: "Cabazitaxel vs docetaxel as 1st line tx for metastatic castration-resistant prostate cancer (FIRSTANA trial) https://t.co/0DliBtSjsc #pcsm https://t.co/ZEHKYfmO8L" / X
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
Cabazitaxel Superior to Switching Antiandrogens for Third-Line mCRPC Treatment - Renal and Urology News
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - The Lancet
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer | SpringerLink
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan | BMC Cancer | Full Text
